Phase 3 Oesophageal Cancer Trial, Recruiting NCT06907602 Sponsor: Peking Union Medical College Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT06907602
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have had their esophageal squamous cell carcinoma (a type of throat/food pipe cancer) confirmed by a laboratory test
  • People whose cancer has been assessed by scans (ultrasound, CT, and MRI) as being at a specific stage — described as T3 or a removable T4 — with or without nearby lymph node involvement
  • People whose cancer has not spread to distant parts of the body, or has spread only to lymph nodes in the neck or above the collarbone
  • People whose tumor measures 10cm or less in length
  • People whose tumor does not affect a specific part of the lower esophagus called the dentate line
  • People with a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
  • People with no blood disorders and no liver or kidney problems
  • People whose blood test results meet specific healthy ranges for white blood cells, platelets, haemoglobin, liver enzymes, and kidney function (confirm with trial site for exact values)
  • People who are willing and able to give informed consent to participate

Who may not be able to join:

  • People whose cancer is assessed as an earlier stage (T1 or T2)
  • People whose scans show the cancer has spread to distant parts of the body
  • People who are pregnant, planning to become pregnant, or currently breastfeeding
  • People who have previously had chemotherapy, radiation therapy, or immunotherapy
  • People with a history of serious heart disease or significant heart failure
  • People with a history of lung scarring (pulmonary fibrosis) or severe lung problems that would make surgery unsafe
  • People who have needed ongoing medical treatment for an autoimmune disease within the past 2 years
  • People with a history of immune system deficiency conditions, or those who require long-term steroid therapy
  • People with a history of nerve-related conditions affecting movement or sensation
  • People with a history of mental illness
  • People with other health conditions that could affect their ability to safely complete the planned treatment, such as serious medication allergies (confirm with trial site)
  • People currently dealing with an active infection that requires treatment
  • People with a history of HIV, hepatitis B (HBV), or hepatitis C (HCV) infection
  • People who have previously received a stem cell or solid organ transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-10-69152630

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
12 January 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological response; 2-year and 5-year overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov